The COPD in LCS Registry will identify and characterize individuals who have functional or radiographic evidence of COPD and are receiving lung cancer screening. Clinical information will be obtained from study participants including symptom burden, lung cancer risk, spirometry, imaging characteristics, and peripheral blood eosinophils.
• * Eligible for lung cancer screening by USPSTF 2021 criteria including age 50-80 years and currently or formerly smoking with at last 20 pack-years of smoking history at the time of consent
Willingness to participate in an observational clinical trial and to be contacted about future ancillary studies that could include interventional clinical trials
Ability to tolerate study procedures
Ability to provide informed consent
Current (i.e. at the time of the visit) GINA Step 4 or higher therapy (medium dose ICS/LABA or high dose ICS or add-on LAMA; medium dose = >250 fluticasone propionate =100 fluticasone furoate, >200 beclomethasone, >400 budesonide, >220 mometasone). We will accept low-dose ICS/LABA or medium dose ICS or
3 or more unscheduled healthcare visits (provider/urgent care/ER) for asthma in the past 12 months or
One asthma hospitalization in the past 12 months
Concurrent participation in a therapeutic trial where treatment is blinded
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Lead sponsor
AstraZeneca
Collaborator